KR910015290A - Improved chemical compounds - Google Patents

Abstract

No content

Description

Improved chemical compounds

Since this is an open matter, no full text was included.

Claims (12)

It consists essentially of a non-toxic ionic polyoxostate compound, mixed with a pharmaceutically acceptable diluent or carrier, which compound has a polyoxo tungstate ion of a metal bundle structure rather than a long structure, which ion from A pharmaceutical composition for antiviral use in a mammal, comprising at least one atom selected from phosphorus, a transition metal and a Group 13 metal. a) [P ₂ H _C W ₁₂ M ' _X O _Y ] ^p- , where M' is a transition metal, x is an integer from 0 or 1 to 6, y is an integer from 48 to 62, c is 0.1 or 2 and p is an integer depending on the oxidation state of the transition metal M '. _{b) [P 2 W 18 M} ; - and _{'4 (H 2 O) 2} O 68] fe 212 ㎠, where M' is a transition metal, p is an integer which depends on the transition metal M 'in the oxidized state. c) [M "W ₁₀ O ₃₅ ] ^n- , where M" is a lanthanide metal and p is a lanthanide metal M "is an integer dependent on oxidation. d) reaction products of silico tungstate ions with Ptx ₂ (PR ₃ ) ₂ or [Pt ₂ (OH ₂ ) ₂ L ₂ ²⁺ ions or phosphotungstate ions with [Pt ₂ (OH ₂ ) ₂ L ₂ ^{2 +} Reaction product of ions. Wherein x is a coordinating anion ligand or X ₂ is a chelating anion ligand, R is an alkyl or aryl group, and each L is an amine or an amine or L ₂ is a chelating amine. e) [P ₂ W _18-a O _62b ] ^p- , or oligomer thereof where a is O or a positive integer of 1 to 5, b is an integer depending on the value of 0 or a, and M ″ is from 5 to Is a metal from 13 widths and P is an integer that depends on the value of a. f) [P ₄ W ₄ O ₅₈ ] ^12- A composition according to claim 1, wherein the polyoxo tungstate ion is formula a). The method of claim 1 wherein the polyoxo tungstate ion is selected from the formula [P ₂ W ₁₂ M ′ _X O _Y ] | composition which is ^p- . No content 2. The composition of claim 1 wherein the polyoxo tungstate ion is of formula e). The composition according to claim 1, wherein the polyoxo tungstate ion is of formula [P ₂ W _18-a O _62-b ] ^P- . 6. The composition of claim 5 wherein the ion is of formula [P ₂ W ₁₅ V ₃ O ₆₂ ] ^q- . 8. A composition according to any one of claims 1 to 7, which is in unit dosage form. 8. Composition according to any one of claims 1 to 7, characterized in that it is in the form of a coating or topical administration composition. The reaction product of PtX ₂ (PR ₃ ) ₂ and silicotungstate ions, wherein X is a coordinating anionic ligand or X ₂ is a chelating anionic ligand and R is an alkyl or aryl group, or each L is an amine or an amine or L ₂ is An ionic platinum polyoxotungstate material, characterized in that it is a reflecting product of [Pt (OH) ₂ L ₂ ] ²⁺ ions that are chelating amines and silicon tungstate or phosphotungstate ions. Use of an ionic polyoxotungstate compound as defined in any one of claims 1 to 10 for the manufacture of a medicament for the treatment of a mammal infected or attacked by a virus. Use according to claim 11, wherein the viral infection is HIV. ※ Note: The disclosure is based on the initial application.